Novo Nordisk plans to launch more than five major drugs by the end of this decade. The Danish pharmaceutical company is trying to stay competitive in the increasingly competitive obesity market. The company said on Monday's capital market day that it aims to achieve pipeline product sales exceeding DKK 150 billion by 2035. The stock fell 7.7% in early trading, and some investors were expecting to see more specific growth targets. CEO Mike Dusdal said at an investor event in London that we need to work harder, and we will do it. Novo Nordisk pioneered the launch of a new generation of potent drugs, making obesity a treatable disease. However, it was difficult for the company to meet demand for pharmaceuticals in the early days, and direct sales to consumers progressed more slowly than its American rival Eli Lilly, and later fell behind Eli Lilly.

Novo Nordisk plans to launch more than five major drugs by the end of this decade. The Danish pharmaceutical company is trying to stay competitive in the increasingly competitive obesity market. The company said on Monday's capital market day that it aims to achieve pipeline product sales exceeding DKK 150 billion by 2035. The stock fell 7.7% in early trading, and some investors were expecting to see more specific growth targets. CEO Mike Dusdal said at an investor event in London that we need to work harder, and we will do it. Novo Nordisk pioneered the launch of a new generation of potent drugs, making obesity a treatable disease. However, it was difficult for the company to meet demand for pharmaceuticals in the early days, and direct sales to consumers progressed more slowly than its American rival Eli Lilly, and later fell behind Eli Lilly.